0 comments
8 forecasters

What will be the reported efficacy outcome of argenx's Phase 3 EMPASSION trial

This question is closed for predictions, and is waiting to be resolved

Superiority28.1%
Non-inferiority only47.8%
Fails non-inferiority.15.1%
Not reported9%